CARDIFF ONCOLOGY INC (CRDF) Stock Price, Forecast & Analysis
NASDAQ:CRDF • US14147L1089
CRDF Key Statistics, Chart & Performance
The current stock price of CRDF is 1.6 USD. In the past month the price decreased by -42.65%. In the past year, price decreased by -62.7%.
CRDF Technical Analysis
CRDF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRDF. CRDF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CRDF Financial Highlights
Over the last trailing twelve months CRDF reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 14.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.42% | ||
| ROE | -103.82% | ||
| Debt/Equity | 0 |
CRDF Forecast & Estimates
15 analysts have analysed CRDF and the average price target is 10.86 USD. This implies a price increase of 578.49% is expected in the next year compared to the current price of 1.6.
For the next year, analysts expect an EPS growth of 17.54% and a revenue growth -24.43% for CRDF
CRDF Ownership
CRDF Latest News, Press Relases and Analysis
CRDF Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRDF
Company Profile
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2004-07-27. The company is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. The company is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The company has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Company Info
CARDIFF ONCOLOGY INC
11055 Flintkote Ave
San Diego CALIFORNIA 92121 US
CEO: Mark Erlander
Employees: 32
Phone: 18589527570
CARDIFF ONCOLOGY INC / CRDF FAQ
What does CRDF do?
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2004-07-27. The company is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. The company is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The company has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
What is the stock price of CARDIFF ONCOLOGY INC today?
The current stock price of CRDF is 1.6 USD. The price increased by 1.27% in the last trading session.
Does CARDIFF ONCOLOGY INC pay dividends?
CRDF does not pay a dividend.
What is the ChartMill rating of CARDIFF ONCOLOGY INC stock?
CRDF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is CARDIFF ONCOLOGY INC (CRDF) stock traded?
CRDF stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for CRDF stock?
CARDIFF ONCOLOGY INC (CRDF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).